Magnasense AB (STO:MAGNA)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0070
-0.0030 (-30.00%)
At close: Jul 17, 2025
-98.36%
Market Cap8.53M
Revenue (ttm)n/a
Net Income (ttm)-49.63M
Shares Out1.45B
EPS (ttm)-1.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,553,895,000
Average Volume263,130,210
Open0.0069
Previous Close0.0100
Day's Range0.0053 - 0.0168
52-Week Range0.0022 - 0.4745
Beta2.26
RSI35.85
Earnings DateSep 2, 2025

About Magnasense AB

Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024. Magnasense AB was incorporated in 2019 and is based in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2019
Employees 15
Stock Exchange Nasdaq Stockholm
Ticker Symbol MAGNA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.